Casdin buys Standard BioTools (LAB) shares worth $1.13 million

Casdin Partners, a significant shareholder in Standard BioTools Inc (NASDAQ:LAB), has recently increased its stake in the company. Between November 13 and November 17, 2025, Casdin purchased a total of 925,000 shares for approximately $1.13 million. The purchases were made at prices ranging from $1.2031 to $1.2392 per share.

The transactions, were executed in multiple purchases. On November 13, 450,000 shares were bought; on November 14, 250,000 shares were bought; and on November 17, 225,000 shares were bought.

Following these transactions, Casdin Partners Master Fund, L.P. directly owns 62,975,000 shares. Casdin Private Growth Equity Fund II, L.P. directly owns 13,939,637 shares, Casdin Private Growth Equity Fund, L.P. directly owns 2,744,219 shares and Eli Casdin directly owns 2,901,062 shares of Standard BioTools Inc.

In other recent news, Standard BioTools Inc. has announced a significant restructuring plan involving a reduction of approximately 15% of its global workforce. This move is part of an effort to enhance operational efficiency and align operating costs with current revenue projections. The company anticipates incurring around $7.5 million in expenses related to this workforce reduction, which will cover cash severance, termination benefits, and other related costs. Additionally, Standard BioTools plans to consolidate its research and development operations from South San Francisco to its Singapore facility. This consolidation will result in a further reduction in workforce among U.S. R&D employees, including some management positions. The company estimates the restructuring will incur an additional $3.6 million in costs, with $0.9 million attributed to non-cash expenses related to the vesting of share-based awards. These recent developments are part of Standard BioTools’ broader strategy to restructure operating expenses and improve operational efficiency.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.